Chemistry:Danuglipron
From HandWiki
Danuglipron is a small-molecule GLP-1 agonist, formerly under development by Pfizer[1] that, in an oral formulation, was under investigation as a therapy for diabetes mellitus. Initial results from a randomized controlled trial indicated that it reduced weight and improved diabetic control. The most commonly reported adverse events were nausea, diarrhea, and vomiting.[2][3] However, in April 2025, Pfizer announced it would abandon further development of Danuglipron due to unpredictable liver toxicity.[4]
See also
References
- ↑ "A Small-Molecule Oral Agonist of the Human Glucagon-like Peptide-1 Receptor". Journal of Medicinal Chemistry 65 (12): 8208–8226. June 2022. doi:10.1021/acs.jmedchem.1c01856. PMID 35647711.
- ↑ "Efficacy and Safety of Oral Small Molecule Glucagon-Like Peptide 1 Receptor Agonist Danuglipron for Glycemic Control Among Patients With Type 2 Diabetes: A Randomized Clinical Trial". JAMA Network Open 6 (5): e2314493. May 2023. doi:10.1001/jamanetworkopen.2023.14493. PMID 37213102.
- ↑ "Pfizer's twice-daily weight loss pill joins a long list of obesity drug flops" (in en). 2023-12-02. https://www.cnbc.com/2023/12/02/pfizer-weight-loss-pill-joins-list-of-obesity-drug-flops.html.
- ↑ "Pfizer scraps daily weight loss pill after liver injury in one patient". April 14, 2025. https://www.cnbc.com/2025/04/14/pfizer-scraps-daily-weight-loss-pill-danuglipron.html.
 |  |
